Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, vol.364, p.2517, 2011. ,
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, vol.384, pp.1109-1126, 2014. ,
Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma, N Engl J Med, vol.373, pp.23-34, 2015. ,
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, vol.369, p.134, 2013. ,
Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer, J Clin Oncol, vol.33, pp.4015-4037, 2015. ,
Phase I Study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors, Clin Cancer Res, vol.21, pp.4286-93, 2015. ,
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-65, 2015. ,
Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, vol.372, pp.2018-2046, 2015. ,
Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, pp.123-158, 2015. ,
Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, vol.33, pp.2004-2016, 2015. ,
Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab, J Clin Oncol, vol.33, pp.2013-2033, 2015. ,
Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, vol.372, pp.320-350, 2015. ,
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol, vol.32, p.1020, 2014. ,
PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, vol.372, pp.311-320, 2015. ,
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial, J Clin Oncol, vol.33, pp.1430-1437, 2015. ,
PD-1 Blockade in tumors with mismatch-repair deficiency, N Engl J Med, vol.372, pp.2509-2529, 2015. ,
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, vol.372, pp.2006-2023, 2015. ,
Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, vol.372, pp.2521-2553, 2015. ,
Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, vol.369, p.122, 2013. ,
Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, pp.1627-1666, 2015. ,
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application, Nat Immunol, vol.14, pp.1212-1220, 2013. ,
PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, vol.26, pp.677-704, 2008. ,
Cancer immunotherapy: rational and recent breakthroughs, Rev Med Interne, issue.16, pp.30413-30414, 2016. ,
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, vol.26, p.2375, 2015. ,
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol Off J Eur Soc Med Oncol ESMO, vol.27, pp.559-74, 2016. ,
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis, BMC Med, vol.13, p.211, 2015. ,
Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer: noteworthy cases, Muscle Nerve, vol.54, p.507, 2016. ,
Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab: MG exacerbation after pembrolizumab, Muscle Nerve, vol.54, pp.157-61, 2016. ,
Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer, Muscle Nerve, vol.52, pp.307-315, 2015. ,
Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions: bullous skin toxicities from anti-PD-1 antibody therapy, J Cutan Pathol, vol.43, pp.688-96, 2016. ,
Severe hyponatremia and immune nephritis following an initial infusion of nivolumab, Target Oncol, vol.11, pp.553-559, 2016. ,
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome, Cancer Immunol Immunother, vol.65, pp.765-772, 2016. ,
Van den Abbeele AD. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT, Clin Nucl Med, vol.40, pp.528-537, 2015. ,
Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma, Chest, vol.149, pp.133-139, 2016. ,
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study, J Immunother Cancer, vol.4, p.13, 2016. ,
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma, J Immunother Cancer, vol.3, issue.1, 2016. ,
Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma, Joint Bone Spine, 2016. ,
Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma, J Immunother, vol.38, pp.37-46, 2015. ,
A case of arthritis under pembrolizumab, Joint Bone Spine, 2016. ,
Immunotherapy-associated hemolytic anemia with pure red-cell aplasia, N Engl J Med, vol.374, pp.1096-1103, 2016. ,
Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma, Melanoma Res, vol.26, pp.202-206, 2016. ,
Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells, Ann Oncol, vol.27, pp.546-553, 2016. ,
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab, Ann Rheum Dis, vol.76, pp.43-50, 2017. ,
Case of hypophysitis caused by nivolumab, J Dermatol, vol.44, pp.109-119, 2017. ,
Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis, JAMA Oncol, vol.2, pp.1607-1623, 2016. ,
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab, Melanoma Res, vol.25, pp.265-273, 2015. ,
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies, Melanoma Res, vol.26, pp.413-419, 2016. ,
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid, J Immunother Cancer, vol.4, p.20, 2016. ,
Endocrine side effects induced by immune checkpoint inhibitors, J Clin Endocrinol Metab, vol.98, p.1361, 2013. ,
Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes, Diabetes Care, vol.38, pp.182-185, 2015. ,
Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy, Diabetes Care, vol.38, pp.55-62, 2015. ,
PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course, Clin Cancer Res, 2016. ,
Treatment of the immunerelated adverse effects of immune checkpoint inhibitors: a review, JAMA Onco, 2016. ,
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor, Eur J Cancer, vol.60, pp.12-25, 2016. ,
Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events, ASCO Annual Meeting Proceedings, vol.33, 2015. ,
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, vol.15, pp.7412-7432, 2009. ,
Evaluation of immune-related response criteria and recist v1.1 in patients with advanced melanoma treated with pembrolizumab, J Clin Oncol, vol.34, pp.1510-1517, 2016. ,
Ipilimumab in patients with melanoma and autoimmune disease, J Immunother Cancer, vol.2, p.35, 2014. ,
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis, J Immunother Cancer, vol.3, p.19, 2015. ,
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma, Mult Scler, vol.21, p.670, 2015. ,
Ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders, JAMA Oncol, vol.2, pp.234-274, 2014. ,
Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease, J Immunother, vol.39, pp.188-90, 2016. ,
Immune-mediated adverse reactions management guide, 2015. ,
A guide to monitoring patients during treatment with Keytruda, 2015. ,
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat Rev Clin Oncol, vol.13, pp.473-86, 2016. ,
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat Rev, vol.45, pp.7-18, 2016. ,
Managing immune checkpoint-blocking antibody side effects, 2015. ,
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial sloan kettering cancer center, J Clin Oncol, vol.33, p.3193, 2015. ,
Toxicities of immunotherapy for the practitioner, J Clin Oncol, vol.33, pp.2092-2101, 2015. ,
Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, Intern Med J, vol.2014, pp.1350-63 ,
Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies, Eur J Pharmacol, vol.771, pp.139-183, 2016. ,
Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients, J Clin Oncol, vol.34, 2016. ,
Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling, Cell, vol.165, pp.272-277, 2016. ,
Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed, Cancer Immunol Res, vol.4, pp.377-82, 2016. ,
Targeted therapies combined with immune checkpoint therapy, Cancer J Sudbury Mass, vol.22, pp.138-184, 2016. ,
Hepatotoxicity with combination of vemurafenib and ipilimumab, N Engl J Med, vol.368, p.1365, 2013. ,
Irradiation and immunotherapy: from concept to the clinic, Cancer, vol.122, pp.1659-71, 2016. ,
Rationale for anti-OX40 cancer immunotherapy, Eur J Cancer Oxf Engl, pp.50-66, 1990. ,
Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy, Cancer Res, vol.76, pp.4931-4971, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01336779
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immunooncology clinical trials, J Immunother Cancer, vol.4, p.15, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01440327
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, vol.20, pp.5064-74, 2014. ,
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade, J. Immunother, vol.31, pp.586-90, 2008. ,
Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study, Cancer Invest, vol.31, pp.336-381, 2013. ,
Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer Oxf Engl, pp.139-187, 1990. ,
Determining predictive factors for immune checkpoint inhibitor toxicity: response to letter to the editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome, Cancer Immunol Immunother, vol.65, pp.765-772, 2016. ,
Intestinal microbiome analyses identify melanoma patients at risk for checkpointblockade-induced colitis, Nat Commun, vol.7, p.10391, 2016. ,
Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab, J Clin Oncol, vol.32, issue.5s, 2014. ,
Skin reactions in a subset of patients with stage IV melanoma treated with anticytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent, Arch Dermatol, vol.142, p.166, 2006. ,
Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis, J Clin Oncol, 2011. ,
Biomarkers associated with checkpoint inhibitors, Ann Oncol, vol.27, pp.1199-206, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01359396
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events, J Transl Med, vol.11, p.75, 2013. ,
Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries, Rheumatol Oxf Engl, vol.50, pp.222-231, 2011. ,